Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 114 entries
Sorted by: Best Match Show Resources per page
[Personal experience in endosseous implants after a few years].

Dental Cadmos

de Vecchi M.
PMID: 350648
Dent Cadmos. 1977 Aug;45(8):3-11.

No abstract available.

Cite
de Vecchi M. Considerazioni su una casistica personale di impianti endoossei a distanza di alcuni anni. [Personal experience in endosseous implants after a few years]. Dent Cadmos. 1977;45(8):3-11
de Vecchi, M. (1977). Considerazioni su una casistica personale di impianti endoossei a distanza di alcuni anni. [Personal experience in endosseous implants after a few years]. Dental Cadmos, 45(8), 3-11.
de Vecchi, M. "Considerazioni su una casistica personale di impianti endoossei a distanza di alcuni anni." [Personal experience in endosseous implants after a few years]. Dental Cadmos vol. 45,8 (1977): 3-11.
de Vecchi M. Considerazioni su una casistica personale di impianti endoossei a distanza di alcuni anni. [Personal experience in endosseous implants after a few years]. Dent Cadmos. 1977 Aug;45(8):3-11. Italian. PMID: 350648.
Copy Download .nbib Format: NLM
Vasopressin Receptor Antagonists for the Correction of Hyponatremia in Chronic Heart Failure: An Underutilized Therapeutic Option in Current Clinical Practice?.

Journal of clinical medicine

De Vecchis R, Cantatrione C, Mazzei D, Baldi C.
PMID: 27706088
J Clin Med. 2016 Oct 02;5(10). doi: 10.3390/jcm5100086.

In the congestive heart failure (CHF) setting, chronic hyponatremia is very common. The present review aims at addressing topics relevant to the pathophysiology of hyponatremia in the course of CHF as well as its optimal treatment, including the main...

Cite
De Vecchis R, Cantatrione C, Mazzei D, et al. Vasopressin Receptor Antagonists for the Correction of Hyponatremia in Chronic Heart Failure: An Underutilized Therapeutic Option in Current Clinical Practice?. J Clin Med. 2016;5(10)doi: 10.3390/jcm5100086.
De Vecchis, R., Cantatrione, C., Mazzei, D., & Baldi, C. (2016). Vasopressin Receptor Antagonists for the Correction of Hyponatremia in Chronic Heart Failure: An Underutilized Therapeutic Option in Current Clinical Practice?. Journal of clinical medicine, 5(10), . https://doi.org/10.3390/jcm5100086
De Vecchis, Renato, et al. "Vasopressin Receptor Antagonists for the Correction of Hyponatremia in Chronic Heart Failure: An Underutilized Therapeutic Option in Current Clinical Practice?." Journal of clinical medicine vol. 5,10 (2016). doi: https://doi.org/10.3390/jcm5100086
De Vecchis R, Cantatrione C, Mazzei D, Baldi C. Vasopressin Receptor Antagonists for the Correction of Hyponatremia in Chronic Heart Failure: An Underutilized Therapeutic Option in Current Clinical Practice?. J Clin Med. 2016 Oct 02;5(10). doi: 10.3390/jcm5100086. PMID: 27706088; PMCID: PMC5086588.
Copy Download .nbib Format: NLM
Change of Serum BNP Between Admission and Discharge After Acute Decompensated Heart Failure Is a Better Predictor of 6-Month All-Cause Mortality Than the Single BNP Value Determined at Admission.

Journal of clinical medicine research

De Vecchis R, Ariano C, Giandomenico G, Di Maio M, Baldi C.
PMID: 27635179
J Clin Med Res. 2016 Oct;8(10):737-42. doi: 10.14740/jocmr2691w. Epub 2016 Aug 30.

BACKGROUND: B-type natriuretic peptide (BNP) is regarded as a reliable predictor of outcome in patients with acute decompensated heart failure (ADHF). However, according to some scholars, a single isolated measurement of serum BNP at the time of hospital admission...

Cite
De Vecchis R, Ariano C, Giandomenico G, et al. Change of Serum BNP Between Admission and Discharge After Acute Decompensated Heart Failure Is a Better Predictor of 6-Month All-Cause Mortality Than the Single BNP Value Determined at Admission. J Clin Med Res. 2016;8(10):737-42doi: 10.14740/jocmr2691w.
De Vecchis, R., Ariano, C., Giandomenico, G., Di Maio, M., & Baldi, C. (2016). Change of Serum BNP Between Admission and Discharge After Acute Decompensated Heart Failure Is a Better Predictor of 6-Month All-Cause Mortality Than the Single BNP Value Determined at Admission. Journal of clinical medicine research, 8(10), 737-42. https://doi.org/10.14740/jocmr2691w
De Vecchis, Renato, et al. "Change of Serum BNP Between Admission and Discharge After Acute Decompensated Heart Failure Is a Better Predictor of 6-Month All-Cause Mortality Than the Single BNP Value Determined at Admission." Journal of clinical medicine research vol. 8,10 (2016): 737-42. doi: https://doi.org/10.14740/jocmr2691w
De Vecchis R, Ariano C, Giandomenico G, Di Maio M, Baldi C. Change of Serum BNP Between Admission and Discharge After Acute Decompensated Heart Failure Is a Better Predictor of 6-Month All-Cause Mortality Than the Single BNP Value Determined at Admission. J Clin Med Res. 2016 Oct;8(10):737-42. doi: 10.14740/jocmr2691w. Epub 2016 Aug 30. PMID: 27635179; PMCID: PMC5012243.
Copy Download .nbib Format: NLM
Ring closure of azo compounds to 1,2-annulated benzimidazole derivatives and further evidence of reversibility of the azo-coupling reaction.

The Journal of organic chemistry

Del Vecchio E, Boga C, Forlani L, Tozzi S, Micheletti G, Cino S.
PMID: 25615685
J Org Chem. 2015 Feb 20;80(4):2216-22. doi: 10.1021/jo5027244. Epub 2015 Feb 03.

The reaction between 1,3,5-tris(N,N-dialkylamino)benzene derivatives and 2 equiv of p-substituted benzenediazonium salts gives dicationic species which collapse to new benzimidazole derivatives with expulsion of p-substituted anilines. The presence of electron-withdrawing groups on the benzenediazo moiety of the dicationic species...

Cite
Del Vecchio E, Boga C, Forlani L, et al. Ring closure of azo compounds to 1,2-annulated benzimidazole derivatives and further evidence of reversibility of the azo-coupling reaction. J Org Chem. 2015;80(4):2216-22doi: 10.1021/jo5027244.
Del Vecchio, E., Boga, C., Forlani, L., Tozzi, S., Micheletti, G., & Cino, S. (2015). Ring closure of azo compounds to 1,2-annulated benzimidazole derivatives and further evidence of reversibility of the azo-coupling reaction. The Journal of organic chemistry, 80(4), 2216-22. https://doi.org/10.1021/jo5027244
Del Vecchio, Erminia, et al. "Ring closure of azo compounds to 1,2-annulated benzimidazole derivatives and further evidence of reversibility of the azo-coupling reaction." The Journal of organic chemistry vol. 80,4 (2015): 2216-22. doi: https://doi.org/10.1021/jo5027244
Del Vecchio E, Boga C, Forlani L, Tozzi S, Micheletti G, Cino S. Ring closure of azo compounds to 1,2-annulated benzimidazole derivatives and further evidence of reversibility of the azo-coupling reaction. J Org Chem. 2015 Feb 20;80(4):2216-22. doi: 10.1021/jo5027244. Epub 2015 Feb 03. PMID: 25615685.
Copy Download .nbib Format: NLM
ANTIBIOTIC-LOADED REGENOSS FOR THE TREATMENT OF SEPTIC BONE DEFECTS: IN VITRO STUDY AND PRELIMINARY CLINICAL EXPERIENCE.

Journal of biological regulators and homeostatic agents

Romano' CL, Gallazzi E, Logoluso N, De Vecchi E, Drago L.
PMID: 26652496
J Biol Regul Homeost Agents. 2015 Oct-Dec;29(4):103-10.

Bone and joint infections are a difficult to treat condition, often associated with bone loss. Although the management of septic bone defects may currently be achieved through various treatment modalities, there is a continuous need for bone substitutes able...

Cite
Romano' CL, Gallazzi E, Logoluso N, et al. ANTIBIOTIC-LOADED REGENOSS FOR THE TREATMENT OF SEPTIC BONE DEFECTS: IN VITRO STUDY AND PRELIMINARY CLINICAL EXPERIENCE. J Biol Regul Homeost Agents. 2015;29(4):103-10
Romano', C. L., Gallazzi, E., Logoluso, N., De Vecchi, E., & Drago, L. (2015). ANTIBIOTIC-LOADED REGENOSS FOR THE TREATMENT OF SEPTIC BONE DEFECTS: IN VITRO STUDY AND PRELIMINARY CLINICAL EXPERIENCE. Journal of biological regulators and homeostatic agents, 29(4), 103-10.
Romano', C L, et al. "ANTIBIOTIC-LOADED REGENOSS FOR THE TREATMENT OF SEPTIC BONE DEFECTS: IN VITRO STUDY AND PRELIMINARY CLINICAL EXPERIENCE." Journal of biological regulators and homeostatic agents vol. 29,4 (2015): 103-10.
Romano' CL, Gallazzi E, Logoluso N, De Vecchi E, Drago L. ANTIBIOTIC-LOADED REGENOSS FOR THE TREATMENT OF SEPTIC BONE DEFECTS: IN VITRO STUDY AND PRELIMINARY CLINICAL EXPERIENCE. J Biol Regul Homeost Agents. 2015 Oct-Dec;29(4):103-10. PMID: 26652496.
Copy Download .nbib Format: NLM
Editorial: Ventricular Mechanics in Congenital Heart Disease.

Frontiers in pediatrics

Biglino G, de Vecchi A.
PMID: 28620598
Front Pediatr. 2017 May 31;5:129. doi: 10.3389/fped.2017.00129. eCollection 2017.

No abstract available.

Cite
Biglino G, de Vecchi A. Editorial: Ventricular Mechanics in Congenital Heart Disease. Front Pediatr. 2017;5:129doi: 10.3389/fped.2017.00129.
Biglino, G., & de Vecchi, A. (2017). Editorial: Ventricular Mechanics in Congenital Heart Disease. Frontiers in pediatrics, 5129. https://doi.org/10.3389/fped.2017.00129
Biglino, Giovanni, and de Vecchi, Adelaide. "Editorial: Ventricular Mechanics in Congenital Heart Disease." Frontiers in pediatrics vol. 5 (2017): 129. doi: https://doi.org/10.3389/fped.2017.00129
Biglino G, de Vecchi A. Editorial: Ventricular Mechanics in Congenital Heart Disease. Front Pediatr. 2017 May 31;5:129. doi: 10.3389/fped.2017.00129. eCollection 2017. PMID: 28620598; PMCID: PMC5449435.
Copy Download .nbib Format: NLM
Hyaluronic Acid and Its Composites as a Local Antimicrobial/Antiadhesive Barrier.

Journal of bone and joint infection

Romanò CL, De Vecchi E, Bortolin M, Morelli I, Drago L.
PMID: 28529865
J Bone Jt Infect. 2017 Jan 01;2(1):63-72. doi: 10.7150/jbji.17705. eCollection 2017.

Living in biofilms is probably the most common condition for bacteria and fungi and biofilm-related infections account for the majority of bacterial infectious diseases worldwide. Among others biofilm-related infections, those associated with implanted biomaterials have an enormous and still...

Cite
Romanò CL, De Vecchi E, Bortolin M, et al. Hyaluronic Acid and Its Composites as a Local Antimicrobial/Antiadhesive Barrier. J Bone Jt Infect. 2017;2(1):63-72doi: 10.7150/jbji.17705.
Romanò, C. L., De Vecchi, E., Bortolin, M., Morelli, I., & Drago, L. (2017). Hyaluronic Acid and Its Composites as a Local Antimicrobial/Antiadhesive Barrier. Journal of bone and joint infection, 2(1), 63-72. https://doi.org/10.7150/jbji.17705
Romanò, C L, et al. "Hyaluronic Acid and Its Composites as a Local Antimicrobial/Antiadhesive Barrier." Journal of bone and joint infection vol. 2,1 (2017): 63-72. doi: https://doi.org/10.7150/jbji.17705
Romanò CL, De Vecchi E, Bortolin M, Morelli I, Drago L. Hyaluronic Acid and Its Composites as a Local Antimicrobial/Antiadhesive Barrier. J Bone Jt Infect. 2017 Jan 01;2(1):63-72. doi: 10.7150/jbji.17705. eCollection 2017. PMID: 28529865; PMCID: PMC5423572.
Copy Download .nbib Format: NLM
Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis?.

Journal of clinical medicine research

De Vecchis R, Noutsias M, Ariano C, Cesaro A, Cioppa C, Giasi A, Maurea N.
PMID: 28270885
J Clin Med Res. 2017 Apr;9(4):266-272. doi: 10.14740/jocmr2933w. Epub 2017 Feb 21.

This review aims at summarizing essential aspects of epidemiology and pathophysiology of hyponatremia in chronic heart failure (CHF), to set the ground for a practical as well as evidence-based approach to treatment. As a guide through the discussion of...

Cite
De Vecchis R, Noutsias M, Ariano C, et al. Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis?. J Clin Med Res. 2017;9(4):266-272doi: 10.14740/jocmr2933w.
De Vecchis, R., Noutsias, M., Ariano, C., Cesaro, A., Cioppa, C., Giasi, A., & Maurea, N. (2017). Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis?. Journal of clinical medicine research, 9(4), 266-272. https://doi.org/10.14740/jocmr2933w
De Vecchis, Renato, et al. "Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis?." Journal of clinical medicine research vol. 9,4 (2017): 266-272. doi: https://doi.org/10.14740/jocmr2933w
De Vecchis R, Noutsias M, Ariano C, Cesaro A, Cioppa C, Giasi A, Maurea N. Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis?. J Clin Med Res. 2017 Apr;9(4):266-272. doi: 10.14740/jocmr2933w. Epub 2017 Feb 21. PMID: 28270885; PMCID: PMC5330768.
Copy Download .nbib Format: NLM
Evidence for carbon-carbon Meisenheimer-Wheland complexes between superelectrophilic and supernucleophilic carbon reagents.

Angewandte Chemie (International ed. in English)

Boga C, Del Vecchio E, Forlani L, Mazzanti A, Todesco PE.
PMID: 15834853
Angew Chem Int Ed Engl. 2005 May 20;44(21):3285-9. doi: 10.1002/anie.200500238.

No abstract available.

Cite
Boga C, Del Vecchio E, Forlani L, et al. Evidence for carbon-carbon Meisenheimer-Wheland complexes between superelectrophilic and supernucleophilic carbon reagents. Angew Chem Int Ed Engl. 2005;44(21):3285-9doi: 10.1002/anie.200500238.
Boga, C., Del Vecchio, E., Forlani, L., Mazzanti, A., & Todesco, P. E. (2005). Evidence for carbon-carbon Meisenheimer-Wheland complexes between superelectrophilic and supernucleophilic carbon reagents. Angewandte Chemie (International ed. in English), 44(21), 3285-9. https://doi.org/10.1002/anie.200500238
Boga, Carla, et al. "Evidence for carbon-carbon Meisenheimer-Wheland complexes between superelectrophilic and supernucleophilic carbon reagents." Angewandte Chemie (International ed. in English) vol. 44,21 (2005): 3285-9. doi: https://doi.org/10.1002/anie.200500238
Boga C, Del Vecchio E, Forlani L, Mazzanti A, Todesco PE. Evidence for carbon-carbon Meisenheimer-Wheland complexes between superelectrophilic and supernucleophilic carbon reagents. Angew Chem Int Ed Engl. 2005 May 20;44(21):3285-9. doi: 10.1002/anie.200500238. PMID: 15834853.
Copy Download .nbib Format: NLM
[Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 year follow-up results].

Minerva gastroenterologica e dietologica

Trepsi E, Colla C, Panizza P, Polino MG, Venturini A, Bottani G, De Vecchi P, Matti C.
PMID: 16498335
Minerva Gastroenterol Dietol. 1999 Dec;45(4):245-52.

In order to evaluate the efficacy and tolerability of mesalazine (5-ASA) in the prophylaxis of symptomatic relapses, of major complications and of microhemorrhagic phenomena in diverticular disease of the large intestine (MDC), prospective clinical study was conducted on patients...

Cite
Trepsi E, Colla C, Panizza P, et al. Ruolo terapeutico e profilattico della mesalazina (5-ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow-up. [Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 year follow-up results]. Minerva Gastroenterol Dietol. 1999;45(4):245-52
Trepsi, E., Colla, C., Panizza, P., Polino, M. G., Venturini, A., Bottani, G., De Vecchi, P., & Matti, C. (1999). Ruolo terapeutico e profilattico della mesalazina (5-ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow-up. [Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 year follow-up results]. Minerva gastroenterologica e dietologica, 45(4), 245-52.
Trepsi, E, et al. "Ruolo terapeutico e profilattico della mesalazina (5-ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow-up." [Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 year follow-up results]. Minerva gastroenterologica e dietologica vol. 45,4 (1999): 245-52.
Trepsi E, Colla C, Panizza P, Polino MG, Venturini A, Bottani G, De Vecchi P, Matti C. Ruolo terapeutico e profilattico della mesalazina (5-ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow-up. [Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 year follow-up results]. Minerva Gastroenterol Dietol. 1999 Dec;45(4):245-52. Italian. PMID: 16498335.
Copy Download .nbib Format: NLM
The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation.

Indian pacing and electrophysiology journal

Murdock DK, Overton N, Kersten M, Kaliebe J, Devecchi F.
PMID: 18679523
Indian Pacing Electrophysiol J. 2008 Aug 01;8(3):175-81.

BACKGROUND: Atrial fibrillation (AF) may arise out of anomalous impulse activity at atrial venous junctions. Triggered activity may be a source of abnormal impulse activity. Ranolazine is an anti-anginal agent, which inhibits normal and abnormal late Na+ channel current...

Cite
Murdock DK, Overton N, Kersten M, et al. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J. 2008;8(3):175-81
Murdock, D. K., Overton, N., Kersten, M., Kaliebe, J., & Devecchi, F. (2008). The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian pacing and electrophysiology journal, 8(3), 175-81.
Murdock, David K, et al. "The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation." Indian pacing and electrophysiology journal vol. 8,3 (2008): 175-81.
Murdock DK, Overton N, Kersten M, Kaliebe J, Devecchi F. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J. 2008 Aug 01;8(3):175-81. PMID: 18679523; PMCID: PMC2490806.
Copy Download .nbib Format: NLM
Secondary Prevention of Atrial Fibrillation: Is It Worth Doing?.

Journal of clinical medicine research

De Vecchis R.
PMID: 30937124
J Clin Med Res. 2019 Apr;11(4):309. doi: 10.14740/jocmr3810. Epub 2019 Mar 18.

No abstract available.

Cite
De Vecchis R. Secondary Prevention of Atrial Fibrillation: Is It Worth Doing?. J Clin Med Res. 2019;11(4):309doi: 10.14740/jocmr3810.
De Vecchis, R. (2019). Secondary Prevention of Atrial Fibrillation: Is It Worth Doing?. Journal of clinical medicine research, 11(4), 309. https://doi.org/10.14740/jocmr3810
De Vecchis, Renato. "Secondary Prevention of Atrial Fibrillation: Is It Worth Doing?." Journal of clinical medicine research vol. 11,4 (2019): 309. doi: https://doi.org/10.14740/jocmr3810
De Vecchis R. Secondary Prevention of Atrial Fibrillation: Is It Worth Doing?. J Clin Med Res. 2019 Apr;11(4):309. doi: 10.14740/jocmr3810. Epub 2019 Mar 18. PMID: 30937124; PMCID: PMC6436569.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 114 entries